4 signals + 7 previous signals in the drug group.
In the pharmaceutical sector, rumblings of interest rate hikes by certain groups may be a catalyst for renewed positive movement in the industry. Of course, as mentioned, there is no longer any expectation of rally-like growth, but the upward trends will continue taking into account temporary corrections and companies with a more attractive P/E.